ChemoCentryx

Amgen’s $3.7B ChemoCentryx acquisition adds a new piece to autoimmune strategy
Health

Amgen’s $3.7B ChemoCentryx acquisition adds a new piece to autoimmune strategy

  Amgen is shelling out almost $4 billion to accumulate ChemoCentryx, the most recent in a string of M&A strikes…
Back to top button
close